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Background: Pazopanib is an oral multitargeted tyrosine-kinase inhibitor, used as a single agent to treat advanced
renal cell carcinoma. Treatment with other tyrosine-kinase inhibitors is known to be associated with asymptomatic
elevations of serum amylase and lipase levels. As regards the pazopanib, data are lacking in literature.
Case presentation: We report one case of pancreatic toxicity associated with pazopanib administration. Before starting
treatment, patient had no risk factors for pancreatitis. The patient, an Italian 68 years old woman, started pazopanib at
doses of 800 mg daily as first-line therapy for metastatic renal cell carcinoma. Six months after the start of treatment,
blood tests showed for the first time a significant increase in serum lipase and amylase in the absence of symptoms and
radiological findings of pancreatitis. The patient continued treatment without interruptions or dose reductions. However,
the continuation of the treatment led to a further increase of pancreatic enzymes. We tried to continue the treatment by
reducing the dose but only the discontinuation was associated with normalization of amylase and lipase’s levels. On the
other hand the treatment with pazopanib got prolonged response of the disease in the absence of signs of pancreatitis.
We therefore decided to continue treatment with pazopanib 400 mg daily with close monitoring of blood levels
of pancreatic enzymes.
Conclusions: We hypothesize that the increase of pancreatic enzymes is not a dose-dependent event. The mechanism
for pancreatic toxicity induced by tyrosine-kinase inhibitors is unknown and no predictive factors have been identified.
There are no clear guidelines on the management of the drug in the presence of pancreatic enzyme increase. In any
case, we believe that a careful monitoring of pancreatic enzymes during treatment with pazopanib is advisable.
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Pazopanib is an oral multitargeted TKI (tyrosine-kinase
inhibitor), used as a single agent to treat advanced renal
cell carcinoma [1]. Treatment with other TKIs such as
sorafenib and sunitinib is known to be associated with
asymptomatic elevations of serum amylase and lipase
levels, which may occur in up to 50 % of patients treated.
Acute pancreatitis has been reported as a rare complica-
tion [2]. As regards the pazopanib, data are lacking: in a
single-arm RCC (Renal Cell Carcinoma) trial, increases in
lipase values were observed for 27 % (48/181) of patients.
In the RCC trials of pazopanib, clinical pancreatitis was
reported in <1 % (4/586) of patients [3].* Correspondence: m.russano@unicampus.it
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We report one case of pancreatic toxicity associated with
pazopanib administration. Before starting treatment, patient
had no risk factors for pancreatitis: no history of alcoholism
or smoking habit, cholelithiasis and biliary-pancreatic infec-
tions; we also excluded by MRI (Magnetic Resonance Im-
aging) or CT-SCAN (Computed Tomography-scan) the
presence of cysts or pancreatic metastasis. This patient, an
Italian 68 years old woman, started pazopanib (800 mg/
die) as first-line therapy for renal cell carcinoma meta-
static to liver and right and left adrenal glands, classified
as favorable-risk according to MSKCC prognostic score
(Memorial Sloan-Kettering Cancer Center score) [4]. The
thorax CT scan and MRI of abdomen performed after 3
and 6 months of treatment showed liver and adrenal
glands partial response. Six months after the start of treat-
ment, blood tests showed for the first time an increase in
serum lipase (2.5 × ULN −Upper Limit of Normal) and
amylase (6 × ULN) in the absence of syntoms and MRIl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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without interruptions or dose reductions. Blood tests
showed a fluctuating trend of lipase and amylase (until
2 × ULN for lipase and 4 ×ULN for amylase) until after
about 18 months of treatment with stable disease, when it
was documented a further significant increase in blood
levels (lipase × 3 ULN and amylase × 5.5 ULN). Discon-
tinuation of the drug led to a sharp reduction in these
levels after only a week: serum lipase level was normal-
ized, while serum amylase level was 4.5 × ULN. But the re-
covery of the treatment led to a persistent asymptomatic
increase in lipase and amylase, therefore short interrup-
tions of the drug were needed. This period of about
6 months was characterized by discontinuous treatment
and parallel ups and downs of pancreatic enzymes. After
2 years and 3 months of treatment with stable disease,
there was a dramatic increase in lipase (5 × ULN; amylase
5.5 × ULN) which led to discontinuation of the drug for
almost a month before the levels for both pancreatic en-
zymes reach normal values. For this reason, the patient
continued treatment with pazopanib at the dose of
600 mg/die. Nevertheless 3 weeks after resumption of
treatment an increase in lipase even more significant was
recorded: lipase 5 ×ULN, amylase 5 ×ULN. As a result of
such events, after restoring the levels of lipase and amyl-
ase, we have decided to continue treatment with pazopa-
nib but further reducing the doses to 400 mg/die. Four
weeks after the start of this new treatment schedule amyl-
ase and lipase showed a new significant increase. We
therefore decided to continue treatment with pazopanib
400 mg/die with close monitoring of blood levels of pancre-
atic enzymes. Throughout the course of treatment, no other
significant alteration was found to blood tests about liver
(transaminase and bilirubin levels) or kidney function (cre-
atinine levels). After 2 months of intermittent pazopanib
400 mg/die, no clinical or radiological signs of pancreatitisFig. 1 Correlation between amylase and lipase serum levels with pazopaniappeared (Fig. 1). Despite repeated dose reductions and
treatment interruptions pazopanib has so far achieved a
prolonged disease control.Discussion
The mechanism for pancreatic toxicity induced by TKIs
is unknown. No predictive factors have been identified.
Hypothetical mechanism regarding acute pancreatitis in-
duced by TKIs is the microvascular ischemia due to the
anti-angiogenic effect that may predispose to pancreatic
inflammation [5]. Other possible mechanism consist in the
activation of pancreatic enzymes caused by the reflux of
duodenal contents induced by decreased gastrointestinal
motility. The increase of pancreatic enzymes could also be
linked to apoptosis of acinar cells induced by inhibition of
VEGF (Vascular Endothelial Growth Factor) [6]. Neverthe-
less specific data regarding pazopanib are lacking in litera-
ture. In the reported case, the increase of pancreatic
enzymes did not appear to be a dose-dependent event.Conclusions
There are no clear guidelines on the management of the
drug in the presence of pancreatic enzyme increase and
no data regarding the real negative predictive role of en-
zyme increase in pancreatitis evolution. Further studies
to identify the mechanisms of pancreatic toxicity and es-
tablish the management and the safety of treatment with
pazopanib are needed. In any case, we believe that a
careful monitoring of pancreatic enzymes during treat-
ment with pazopanib is advisable. Hypothetically, the in-
crease of pancreatic enzymes in the absence of obvious
signs of pancreatitis may require changes to the schedule
of treatment with pazopanib but not necessarily lead to
a prolonged suspension of the treatment.b administration
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Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor of this journal.
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